1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Variables associated with mortality at 1-month follow-up
Mortality (n = 7)Survival (n = 28)P
Men (No.) (%)4 (57.1)19 (67.9).593
Age (mean) (SD) (yr)77.43 (10.85)70.93 (13.1).235
Prior antiplatelet therapy (No.) (%)2 (28.6)4 (15.4).422
Prior anticoagulant therapy (No.) (%)1 (14.3)3 (11.5).843
Previous use of statins (No.) (%)1 (14.3)2 (7.7).590
Baseline NIHSS (median) (IQR)23 (16–24)7 (3–14)<.001
Baseline GCS (median) (IQR)10 (4–15)15 (15–15).007
Systolic BP at admission (mean) (SD) (mm Hg)164.86 (37.9)169.09 (31.99).771
Blood glucose level at admission (mean) (SD) (mg/dL)152 (20.14)133.86 (52.34).381
Platelet count/mm3 at admission (mean) (SD)222,714 (89,582)219,840 (73,803).931
Baseline HV measured with CT (median) (IQR) (mL)98.51 (80.68–124.01)6.85 (1.95–38.06)<.001
Baseline MLS measured with CT (median) (IQR) (cm)0.88 (0.56–1.48)0 (0–0.18).001
Significant HG assessed with CT (No.) (%) (mL)a1 (100)1 (5.6).105
Baseline HV measured with TDS (median) (IQR)59.13 (33.82–85.42)8.62 (3.69–21.56)<.001
Baseline MLS measured with TDS (median) (IQR) (cm)0.4 (0.29–1.45)0.09 (0.04–0.16).001
Pulsatility index from the ipsilateral MCA (mean) (SD) (cm/s)1.54 (0.45)1.2 (0.34).033
Pulsatility index from the contralateral MCA (mean) (SD) (cm/s)1.37 (0.36)1.12 (0.27).058
Lobar localization (No.) (%)6 (85.7)10 (35.7).018
IVH (No.) (%)4 (44.4)6 (23.1).393
  • Note:—GCS indicates Glasgow Coma Scale; IVH, intraventricular hemorrhage; BP, blood pressure; HG, hematoma growth.
  • ↵a Analysis was restricted to 21 patients for whom a follow-up CT scan was available.